



Press Release

Martinsried/Munich, Germany, September 1, 2010

MorphoSys to Present at Three Investor Conferences in September

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its management will give company presentations at the following upcoming investor conferences:

German Healthcare Conference

Date: September 8, 2010 at 01:40pm CET (12:40pm BST; 07:40am EDT)

Venue: Zurich, Switzerland

Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

Rodman & Renshaw Annual Global Investment Conference

Date: September 13, 2010 at 10:00am EDT (03:00pm BST; 04:00pm CET)

Venue: New York, USA

Presenter: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations

UBS Global Life Sciences Conference

Date: September 20, 2010 at 12:00pm EDT (05:00pm BST; 06:00pm CET)

Venue: New York, USA

Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

The PDF versions and, if available, live and archived webcasts of the presentations will be provided at www.morphosys.com.

About MorphoSys:

MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit <http://www.morphosys.com/>

HuCAL[®], HuCAL GOLD[®], HuCAL PLATINUM[®], CysDisplay[®] and RapMAT[®] are registered trademarks of MorphoSys.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

investors@morphosys.com